Tarsus Pharmaceuticals, Inc. TARS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$48.27M+54.0% | -$66.42M+42.5% | -$81.16M+39.6% | -$91.99M+38.7% | -$104.94M+29.2% | ||
| $799K+12.2% | $822K+24.2% | $812K+13.2% | $812K+13.2% | $712K-12.9% | ||
| $46.76M+60.0% | $41.72M+50.0% | $34.81M+34.4% | $29.98M+26.3% | $29.23M+36.3% | ||
| $613K+20.9% | $593K+23.0% | $575K+26.4% | $552K+29.3% | $507K+21.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.9M— | $1.79M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $511K+181% | $527K+186% | $146K+129% | -$252K+33.2% | -$633K-197% | ||
| $20.25M+3,260% | -$1.72M-124% | $14.17M+1,103% | $23.3M+2,735% | -$641K-131% | ||
| $881K+29.6% | $881K+63.1% | $880K+120% | $780K+160% | $680K+240% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$80.87M+34.7% | -$65.89M+50.6% | ||
| $15.09M+661% | $9.86M+529% | $3.57M+139% | $1.95M+22.5% | $1.98M+48.4% | ||
| $394.42M+39.1% | $393.19M+49.7% | $447.57M— | $366.33M— | $283.65M— | ||
| —— | —— | -$150.96M-20.9% | -$146.22M-88.6% | -$135.04M-599% | ||
| —— | —— | —— | —— | —— | ||
| $8.03M-95.6% | $143.39M-7.3% | $144M-16.0% | $142.08M-48.5% | $182.45M-22.0% | ||
| —— | —— | —— | —— | -$15.36M-112% | ||
| $8.24M-7.1% | $8.34M+8.9% | $8.46M+33.5% | $10.49M+260% | $8.87M+181% | ||
| —— | —— | —— | —— | —— | ||
| $5.02M-4.2% | $5.48M+30.1% | $6.04M+111% | $5.65M+157% | $5.24M+166% | ||
| $613K+20.9% | $593K+23.0% | $575K+26.4% | $552K+29.3% | $507K+21.3% | ||
| $881K+29.6% | $881K+63.1% | $880K+120% | $780K+160% | $680K+240% | ||
| $799K+12.2% | $822K+24.2% | $812K+13.2% | $812K+13.2% | $712K-12.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $38.51M+141% | ||
| —— | —— | —— | —— | —— | ||
| $20.25M+3,260% | -$1.72M-124% | $14.17M+1,103% | $23.3M+2,735% | -$641K-131% | ||
| $595K-10.8% | $682K+7.4% | $701K+18.2% | $663K+20.3% | $667K+27.8% | ||
| $2.4M+1,641% | $1.53M+1,446% | $1.54M+863% | $440K+279% | $138K+3.0% | ||
| -$354K— | $0— | $3K— | —— | —— | ||
| —— | $0-100% | $269.5K-66.7% | $539K0.0% | $808.5K+200% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$82.82M+34.0% | -$67.87M+49.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Tarsus Pharmaceuticals, Inc. generate?
- Tarsus Pharmaceuticals, Inc. (TARS) generated -$96.9M in operating cash flow over the trailing twelve months.
- What is Tarsus Pharmaceuticals, Inc.'s free cash flow?
- After $15.1M of capital expenditures, Tarsus Pharmaceuticals, Inc.'s free cash flow was -$104.4M over the trailing twelve months, down 2.6% year over year.
- Where does Tarsus Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
